Clarivate (CLVT) Set to Release Earnings on Tuesday

Clarivate (NYSE:CLVT) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.1772 per share and revenue of $566.77 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Clarivate (NYSE:CLVT) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. The firm had revenue of $587.30 million during the quarter, compared to the consensus estimate of $589.73 million. Clarivate had a positive return on equity of 9.15% and a negative net margin of 13.84%. The business’s revenue was down 5.5% compared to the same quarter last year. During the same period last year, the company earned $0.18 earnings per share. On average, analysts expect Clarivate to post $0.67 EPS for the current fiscal year and $0.67 EPS for the next fiscal year.

Clarivate Stock Up 0.2%

NYSE:CLVT opened at $1.87 on Tuesday. Clarivate has a twelve month low of $1.42 and a twelve month high of $3.87. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -3.60 and a beta of 1.40. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.93. The stock’s 50 day moving average price is $1.84 and its two-hundred day moving average price is $2.26.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CLVT. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research report on Monday, September 21st. Wall Street Zen downgraded shares of Clarivate from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. The Goldman Sachs Group reduced their price target on Clarivate from $2.90 to $2.60 and set a “neutral” rating for the company in a report on Thursday, July 30th. William Blair downgraded Clarivate to a “market perform” rating in a research report on Thursday, October 15th. Finally, Stifel Nicolaus lowered their price target on Clarivate from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $3.02.

Insiders Place Their Bets

In related news, Director Kenneth Cornick acquired 650,000 shares of Clarivate stock in a transaction on Thursday, August 6th. The stock was purchased at an average cost of $1.86 per share, with a total value of $1,209,000.00. Following the completion of the transaction, the director directly owned 1,750,000 shares in the company, valued at $3,255,000. This trade represents a 59.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew Snyder sold 2,489,618 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $1.94, for a total transaction of $4,829,858.92. Following the completion of the transaction, the director owned 3,856,597 shares in the company, valued at approximately $7,481,798.18. This represents a 39.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 22.88% of the company’s stock.

Clarivate Company Profile

Clarivate Plc (NYSE:CLVT) provides analytics, data, and workflow solutions to organizations in academia, government, research, life sciences, and intellectual property. Its offerings are designed to help customers evaluate research, manage information, accelerate innovation, and support strategic decision-making.

The company’s products include Web of Science research databases and citation analytics, InCites research evaluation tools, Derwent innovation and patent intelligence services, and Cortellis life sciences and drug-development information.